These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18765198)

  • 1. Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support.
    Lick SD; Vaidya S; Kollar AC; Boor PJ; Vertrees RA
    J Heart Lung Transplant; 2008 Sep; 27(9):1036-9. PubMed ID: 18765198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab.
    Lick SD; Beckles DL; Piovesana G; Vaidya S; Indrikovs A; Barbagelata NA; Valentine V
    Ann Thorac Surg; 2011 Oct; 92(4):1428-34. PubMed ID: 21855854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
    Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE
    J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.
    Kute VB; Vanikar AV; Trivedi HL; Shah PR; Goplani KR; Patel HV; Gumber MR; Patel RD; Kanodia KV; Suthar KS; Trivedi VB; Modi PR
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):662-9. PubMed ID: 21743208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in highly sensitized kidney transplant recipients.
    Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful bridge to transplant in a highly sensitized patient with a complicated pump pocket infection.
    McGee EC; Cotts W; Tambur AR; Friedewald J; Kim J; O'Connell J; Wallace S; McCarthy PM
    J Heart Lung Transplant; 2008 May; 27(5):568-71. PubMed ID: 18442726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
    Ona ET; Danguilan RA; Africa J; Cabanayan-Casasola CB; Antonio ZL; Gutierrez-Marbella MA; dela Cruz R; Bumanglag N; Espedilla ME
    Transplant Proc; 2008 Sep; 40(7):2226-9. PubMed ID: 18790199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Right heart failure and "failure to thrive" after left ventricular assist device: clinical predictors and outcomes.
    Baumwol J; Macdonald PS; Keogh AM; Kotlyar E; Spratt P; Jansz P; Hayward CS
    J Heart Lung Transplant; 2011 Aug; 30(8):888-95. PubMed ID: 21530314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
    Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
    Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive panel reactive antibody titers in patients bridged to transplantation with a mechanical assist device: risk factors and treatment.
    Tsau PH; Arabía FA; Toporoff B; Paramesh V; Sethi GK; Copeland JG
    ASAIO J; 1998; 44(5):M634-7. PubMed ID: 9804512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis.
    Thielke J; DeChristopher PJ; Sankary H; Oberholzer J; Testa G; Benedetti E
    Transplant Proc; 2005 Mar; 37(2):643-4. PubMed ID: 15848486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices.
    Zimpfer D; Zrunek P; Sandner S; Schima H; Grimm M; Zuckermann A; Wolner E; Wieselthaler G
    Eur J Cardiothorac Surg; 2007 Apr; 31(4):698-702. PubMed ID: 17289396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch.
    Wright EJ; Fiser WP; Edens RE; Frazier EA; Morrow WR; Imamura M; Jaquiss RD
    J Heart Lung Transplant; 2007 Nov; 26(11):1163-9. PubMed ID: 18022083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.